Cidara Therapeutics Acquired, Delisted from Nasdaq Following Tender Offer Completion
Summary
Cidara Therapeutics, Inc. has been acquired and delisted from the Nasdaq Stock Market following the successful completion of a tender offer and subsequent merger, making it a wholly-owned subsidiary.
Key Events
-
Tender Offer Completed
The tender offer for Cidara Therapeutics shares expired on January 6, 2026, with a sufficient number of shares validly tendered to satisfy the minimum condition.
-
Merger Consummated
On January 7, 2026, the purchaser merged with Cidara Therapeutics, making the company a wholly-owned subsidiary of the 'Parent' entity.
-
Delisting from Nasdaq
Following the merger, Cidara Therapeutics' common stock was deregistered under the Securities Exchange Act and ceased to be listed for trading on the Nasdaq Stock Market.
-
RA Capital Exits Position
RA Capital Management, L.P. and its affiliated funds tendered all 3,365,523 Common Shares and 89,956 Series A Shares, ceasing to be beneficial owners of more than five percent of the common stock.
Analysis
This filing confirms the definitive acquisition of Cidara Therapeutics, Inc. by an undisclosed 'Parent' entity. The successful tender offer and subsequent merger mean that Cidara is no longer an independent, publicly traded company. Shareholders who tendered their shares received cash consideration, and the stock has been delisted from Nasdaq. All outstanding shares, options, and warrants were converted into cash or cancelled. RA Capital Management, a significant institutional investor, fully exited its position by tendering all its shares. This event represents a complete change in the investment thesis for Cidara, as the company's public trading existence has concluded.
At the time of this filing, CDTX was trading at $221.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7B. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.